Search | Clinical Trials Finder

Conditions: Hypophosphatemic Rickets, X-Linked Dominant
Interventions: Cinacalcet; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 5 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hip Osteoarthritis, Complications; Arthroplasty
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions: ALLO-329, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 13
States / cities: Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 10 more

Conditions: Endometrial Cancer, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 15,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions: Kidney disease; Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pain, Low Back Pain, Fibromyalgia, Upper Extremity Dysfunction, Complex Regional Pain Syndromes, Phantom Limb Pain, Rheumatoid Arthritis, Carpal Tunnel Syndrome, Repetitive Strain Injury
Interventions: Karuna Labs Virtual Reality Software; Device
Lead sponsor: Karuna Labs Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions: DiNaMo Study App, Placebo App; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Diabetic Foot Ulcer (DFU), Lower Extremity
Interventions: Graft Application, Wound Dressing Material; Other
Lead sponsor: LifeNet Health; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Tucson, Arizona • Castro Valley, California • Fresno, California + 14 more

Conditions: Cleft Palates
Interventions: Unasyn, saline solution; Drug · Other
Lead sponsor: Joseph Losee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions: Oral dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Dup15Q Syndrome, Duchenne Muscular Dystrophy, Phelan-McDermid Syndrome, Rett Syndrome, Smith Magenis Syndrome, Williams Syndrome, Turner Syndrome, Klinefelter Syndrome, Chromosome 22q11.2 Deletion Syndrome, Tuberous Sclerosis, Down Syndrome
Interventions: Parent-Infant Inter(X)action Intervention (PIXI); Behavioral
Lead sponsor: RTI International; Other
Eligibility: Up to 99 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Interventions: Observation; Other
Lead sponsor: Tempus AI; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Pain, Postoperative, Regional Anesthesia, Hip Dysplasia
Interventions: Erector spinae block with ropivacaine 0.2%, Quadratus lumborum block with ropivacaine 0.2%, Ropivacaine; Procedure · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperphosphatemia
Interventions: Niacinamide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Osteoarthritis, Knee, Total Knee Arthroplasty, Chronic Postsurgical Pain
Interventions: GlyNAC (combination of glycine and n-acetylcysteine), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pain, Post-operative
Interventions: Intranasal Dexmedetomidine, Intranasal Placebo; Drug
Lead sponsor: Baudax Bio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Bakersfield, California • Pasadena, California • San Antonio, Texas

Conditions: Lumbar Spondylolisthesis, Lumbar Spine Degeneration
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency
Interventions: Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more

Conditions: X-linked Hypophosphatemia
Interventions: burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 5 Years to 12 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more

Conditions: Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: levofloxacin; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 78
States / cities: Little Rock, Arkansas • Downey, California • Duarte, California + 65 more

Conditions: Post Operative Pain, Osteoarthritis, Knee
Interventions: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 35 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions: venipuncture, Questionnaires, Additional Sample Collections; Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years and older
Enrollment: 120,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

Correlation of Spinopelvic Parameters and Acetabular Cup Orientation

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Bone Mineral Density and Subsequent Cancer Risk

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

Preventing Complications in Cleft Palate Repair With Antibiotics

Steroid Treatment for Kidney Disease

Parent and Infant Inter(X)Action Intervention (PIXI)

Tempus Priority Study: A Pan-tumor Observational Study

Quadratus Lumborum vs Erector Spinae Supplementary Blocks With Lumbar Plexus Blocks for Hip PAO

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty

Familial Investigations of Childhood Cancer Predisposition

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery

Comparison of Complication Rates Between Initial and Re-operative Anterior Lumbar Interbody Fusion Surgery: Is There a Difference?

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

ZYNRELEF for Pain Management in Total Knee Arthroplasty

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study